Pancreatic Cancer
Conditions
Interventions
Focused Ultrasound Surgery (FUS) combined with chemotherapy group:NA
chemotherapy alone group:NA
Sponsors
The Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Having given personal consent and signed the informed consent form, and being willing and able to comply with the planned visits, study treatments, laboratory tests, and other trial procedures; (2) Patients with pancreatic cancer confirmed by histopathology or clinically diagnosed by enhanced computed tomography (CT), magnetic resonance imaging (MRI), or other relevant examinations; (3) Diagnosed as stage III/IV according to the 2018 NCCN Guidelines (Version 8) for pancreatic cancer TNM staging criteria; (4) Unresectable by radical pancreatic cancer surgery; (5) Aged 18 to 75 years; (6) No previous history of radical surgical treatment, radiotherapy, or systemic therapy for pancreatic cancer; (7) Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; (8) Having clearly measurable lesions that meet the requirements of the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1), with the maximum diameter >= 20 mm; (9) Expected survival time of at least 12 weeks; (10) Planned to receive treatment with "gemcitabine + nab-paclitaxel", "liposomal irinotecan (II) + oxaliplatin + fluorouracil + leucovorin", "oral capecitabine", or "oral tegafur-gimeracil-oteracil potassium", either alone or in combination with FUS.
Exclusion criteria
Exclusion criteria: (1) Having previously received radiotherapy or focused ultrasound surgery (FUS) within 12 weeks; (2) Not eligible for treatment with "gemcitabine + nab-paclitaxel", "liposomal irinotecan (II) + oxaliplatin + fluorouracil + leucovorin", "oral capecitabine", or "oral tegafur-gimeracil-oteracil potassium", either alone or in combination with FUS; (3) Pregnant or lactating women; (4) Patients with other severe physical or mental illnesses, or abnormal laboratory test results, which may increase the risk of participating in the study, interfere with the study results, or are deemed unsuitable for participation in this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival, OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival, PFS;objective response rate, ORR;disease control rate, DCR;safety;pain intensity; | — |
Countries
China
Contacts
Public ContactYunfei Liu
The Third Xiangya Hospital of Central South University
Outcome results
None listed